25.97

4.15% -1.00

Odyssey Therapeutics Inc (ODTX)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$26.97

Offen:

$26.97

24-Stunden-Volumen:

72,011

Relative Volume:

0.28

Marktkapitalisierung:

$1.25B

Einnahmen:

Nettoeinkommen (Verlust:

KGV:

-8.3912

EPS:

-3.0949

Netto-Cashflow:

1W Leistung:

-2.89%

1M Leistung:

+22.11%

6M Leistung:

+0.00%

1J Leistung:

+0.00%

1-Tages-Spanne:

$25.62

$28.26

1-Wochen-Bereich:

$25.62

$29.05

52-Wochen-Spanne:

$15.10

$29.05

Odyssey Therapeutics Inc Stock (ODTX) Company Profile

Firmenname

Odyssey Therapeutics Inc

Sektor

Healthcare (1086)

Branche

Biotechnology (606)

Telefon

(212) 841-1000

Adresse

51 SLEEPER STREET, BOSTON

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-09-16

Neueste SEC-Einreichungen

ODTX's Discussions on Twitter

Compare ODTX vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ODTX Odyssey Therapeutics Inc	25.96	1.30B	0	0	0	-3.0949
VRTX Vertex Pharmaceuticals Inc	521.17	134.06B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.04	83.43B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,004.37	63.00B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	137.39	56.02B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.19	44.44B	742.00K	-1.37B	-1.07B	-7.0731

Odyssey Therapeutics Inc Aktie (ODTX) Neueste Nachrichten

06:03 AM

Odyssey Therapeutics posts September 2026 presentation detailing OD-001 Phase 2a success, $433M cash runway into H2 2028 - TradingView

06:03 AM

Sep 08, 2026

ODTX Price Today: Odyssey Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC

Sep 08, 2026

RIPK2 inhibitors reported in Odyssey Therapeutics patent - BioWorld News

Sep 08, 2026

Sep 04, 2026

Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower - Stocktwits

Sep 04, 2026

Odyssey Therapeutics, Inc. Common Stock (NASDAQ: ODTX) Stock Price, News & Analysis - Kalkine

Sep 04, 2026

Aug 31, 2026

Q3 Earnings Forecast for ODTX Issued By HC Wainwright - marketbeat.com

Aug 31, 2026

Aug 27, 2026

Odyssey Therapeutics to Participate in Upcoming Investor Conferences - Moomoo

Aug 27, 2026

This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Sahm

Aug 27, 2026

Aug 19, 2026

Top Odyssey Therapeutics (ODTX) Competitors 2026 - MarketBeat

Aug 19, 2026

Aug 13, 2026

Odyssey Therapeutics (ODTX) Stock Trends and Sentiment 2026 - marketbeat.com

Aug 13, 2026

Aug 11, 2026

J.P. Morgan Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Raises Target Price to $29 - Moomoo

Aug 11, 2026

Aug 10, 2026

Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention - Yahoo Finance

Aug 10, 2026

Odyssey Therapeutics (ODTX) Stock Looks Reasonable As AI Research News Lands - Sahm

Aug 10, 2026

Aug 09, 2026

Odyssey Therapeutics Ord Shs (Proposed) (ODTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Aug 09, 2026

Aug 07, 2026

Evotec and Odyssey Forge AI-Powered Drug Discovery Pact Targeting Autoimmune Diseases - finance.biggo.com

Aug 07, 2026

Odyssey Therapeutics (NASDAQ:ODTX) Given New $29.00 Price Target at JPMorgan Chase & Co. - MarketBeat

Aug 07, 2026

Analysts Offer Insights on Healthcare Companies: Biodesix (BDSX), Pacific Biosciences (PACB) and Odyssey Therapeutics, Inc. (ODTX) - The Globe and Mail

Aug 07, 2026

Aug 06, 2026

EQS-News: Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - sharewise.com

Aug 06, 2026

Odyssey Therapeutics: Q2 Earnings Snapshot - marketscreener.com

Aug 06, 2026

Odyssey Therapeutics, Inc. Q2 2026: Revenue $0 EPS $(1.74) — 10-Q Summary - TradingView

Aug 06, 2026

Biotech Stocks At 52-Week HighsBVS, TVTX, ODTX, CRL Climb With Q2 Results, ACRS - RTTNews

Aug 06, 2026

Evotec and Odyssey Pair AI With Lab Tests for Immune Diseases - Stock Titan

Aug 06, 2026

Evotec Se and Odyssey Therapeutics, Inc. Enter Ai-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - marketscreener.com

Aug 06, 2026

Evotec : and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - marketscreener.com

Aug 06, 2026

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - Yahoo Finance

Aug 06, 2026

Aug 04, 2026

Odyssey Therapeutics (ODTX) Institutional Ownership 2026 - marketbeat.com

Aug 04, 2026

Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times

Aug 04, 2026

Odyssey Therapeutics reports Q2 2026 net loss $52.8M; cash $433.1M to fund into 2H 2028 - TradingView

Aug 04, 2026

Jul 27, 2026

Odyssey Therapeutics, Inc. Revenue Breakdown – NASDAQ:ODTX - TradingView

Jul 27, 2026

Jul 25, 2026

ODTX|Odyssey Therapeutics Ord Shs (Proposed)|Price:18.660|Chg%:+0.990 - TradingKey

Jul 25, 2026

Jul 14, 2026

Odyssey Therapeutics (ODTX) Earnings Date and Reports 2026 - MarketBeat

Jul 14, 2026

Jul 09, 2026

Enterprise value to EBITDA forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView

Jul 09, 2026

Enterprise value to revenue forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView

Jul 09, 2026

Price to book forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView

Jul 09, 2026

Price to earnings forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView

Jul 09, 2026

Price to sales forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView

Jul 09, 2026

Jul 05, 2026

Odyssey Therapeutics prices upsized IPO at $18 per share - Investing.com

Jul 05, 2026

Jul 03, 2026